From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

著者: Bersanelli, Melissa, Buti, Sebastiano
出版年 World J Clin Oncol (2017)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

著者: Bersanelli, Melissa, Buti, Sebastiano
出版年 Ther Adv Med Oncol (2017)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

著者: Bersanelli, Melissa, Leonardi, Francesco, Buti, Sebastiano
出版年 Cancer Manag Res (2018)

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a “transcriptomic compass”?

著者: Bersanelli, Melissa, Cortellini, Alessio, Buti, Sebastiano
出版年 Ann Transl Med (2019)

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”...

著者: Bersanelli, Melissa, Cortellini, Alessio, Buti, Sebastiano
出版年 Hum Vaccin Immunother (2021)

Systemic adjuvant therapies in renal cell carcinoma

著者: Buti, Sebastiano, Bersanelli, Melissa, Donini, Maddalena, Ardizzoni, Andrea
出版年 Oncol Rev (2012)

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report

著者: Bordi, Paola, Tiseo, Marcello, Baldari, Giorgio, Buti, Sebastiano
出版年 BMC Cancer (2016)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

著者: Buti, Sebastiano, Leonetti, Alessandro, Dallatomasina, Alice, Bersanelli, Melissa
出版年 Core Evid (2016)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

著者: Leonetti, Alessandro, Leonardi, Francesco, Bersanelli, Melissa, Buti, Sebastiano
出版年 Ther Clin Risk Manag (2017)

Family history of cancer and DNA damage response genes: Two sides of the same coin?

著者: Cortellini, Alessio, Bersanelli, Melissa, Ficorella, Corrado, Buti, Sebastiano
出版年 Thorac Cancer (2018)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

著者: Facchinetti, Francesco, Bordi, Paola, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello
出版年 Drug Des Devel Ther (2018)

Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions

著者: Bersanelli, Melissa, Buti, Sebastiano, Santoni, Matteo, Ziglioli, Francesco, Maestroni, Umberto
出版年 Ann Transl Med (2019)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

著者: Bersanelli, Melissa, Brunelli, Matteo, Gnetti, Letizia, Maestroni, Umberto, Buti, Sebastiano
出版年 Ther Adv Med Oncol (2020)

Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the “embarrassment of riches”

著者: Buti, Sebastiano, Leonetti, Alessandro, Lattanzi, Elisabetta, D’Abbiero, Nunziata, Bersanelli, Melissa
出版年 Ann Transl Med (2019)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

著者: Buti, Sebastiano, Donini, Maddalena, Bersanelli, Melissa, Gattara, Alessia, Leonardi, Francesco, Passalacqua, Rodolfo
出版年 Drugs R D (2017)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

著者: Buti, Sebastiano, Donini, Maddalena, Bersanelli, Melissa, Gattara, Alessia, Leonardi, Francesco, Passalacqua, Rodolfo
出版年 Drugs R D (2018)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

著者: Bersanelli, Melissa, Buti, Sebastiano, Camisa, Roberta, Brighenti, Matteo, Lazzarelli, Silvia, Mazza, Giancarlo, Passalacqua, Rodolfo
出版年 Cancers (Basel) (2014)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

著者: Roviello, Giandomenico, Buti, Sebastiano, Cattrini, Carlo, Mennitto, Alessia, Messina, Carlo, Airoldi, Chiara, Vannini, Gianmarco, Bersanelli, Melissa
出版年 Ther Adv Urol (2021)

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

著者: Bersanelli, Melissa, Giannarelli, Diana, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello, Nouvenne, Antonio, Ticinesi, Andrea, Meschi, Tiziana, Procopio, Giuseppe, Danielli, Riccardo
出版年 Future Oncol (2021)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

著者: Dall’Olio, Filippo G., Abbati, Francesca, Facchinetti, Francesco, Massucci, Maria, Melotti, Barbara, Squadrilli, Anna, Buti, Sebastiano, Formica, Francesca, Tiseo, Marcello, Ardizzoni, Andrea
出版年 Ther Adv Med Oncol (2020)